サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1683388

ナノテクノロジー対応ドラッグデリバリーデバイスの世界市場：2025年～2033年

Global Nanotechnology-Enabled Drug Delivery Devices Market - 2025-2033

出版日
ページ情報
英文 159 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ナノテクノロジー対応ドラッグデリバリーデバイスの世界市場：2025年～2033年
出版日: 2025年03月20日
発行: DataM Intelligence
ページ情報: 英文 159 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のナノテクノロジー対応ドラッグデリバリーデバイスの市場は、2024年に542億2,000万米ドルに達し、2033年には1,791億2,000万米ドルに達すると予測され、予測期間2025年のCAGRは12.6%になるとみられています。

ナノテクノロジー対応ドラッグデリバリーデバイスは、ナノテクノロジーを利用して治療薬の有効性、精度、安全性を向上させる先進的なシステムです。これらのデバイスは、ナノ粒子、リポソーム、デンドリマー、高分子ミセルのようなナノスケール材料を使用し、薬剤の溶解性、生物学的利用能、特定の組織や細胞への標的送達を向上させる。これらのシステムは副作用を最小限に抑え、治療成果を高め、特に腫瘍学、神経学、感染症治療において個別化治療アプローチを可能にします。

世界のナノテクノロジー対応ドラッグデリバリーデバイス市場は、薬剤のバイオアベイラビリティと標的デリバリーを改善する能力により拡大しています。これらのシステムは、薬剤を特定の組織や疾患細胞に送達することで治療効果を高め、副作用を最小限に抑えます。これらのシステムは、溶解性を改善し、循環時間を延長し、薬剤の放出を制御できるため、腫瘍学、神経学、心臓血管系疾患において特に有用です。これらの技術革新はまた、生物学的障壁を越えた薬剤輸送を促進し、複雑な病態の治療に不可欠なものとなっています。

世界のナノテクノロジー対応ドラッグデリバリーデバイス市場は、精密エンジニアリング、専門施設、厳格な品質管理対策など、大規模製造の複雑さによる大きな課題に直面しています。ナノ粒子のサイズ、安定性、薬剤充填効率のばらつきは製品の一貫性に影響を与え、規制上の後退につながる可能性があります。高度な製造インフラを維持し、バッチ間の均一性を確保することに関連する高コストは、市場の拡大をさらに制限し、ドラッグデリバリーにおけるナノテクノロジーの普及を制限しています。

当レポートでは、世界のナノテクノロジー対応ドラッグデリバリーデバイス市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブの洞察と重要なポイント

第3章 市場力学

  • 影響要因
    • 促進要因
    • 抑制要因
    • 機会
    • 影響分析

第4章 戦略的洞察と業界の展望

  • 市場のリーダーと先駆者
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 製品タイプ別

  • ナノ結晶
  • ナノ粒子
  • リポソーム
  • ミセル
  • ナノチューブ
  • その他

第6章 用途別

  • 神経
  • 腫瘍
  • 心臓血管/生理
  • 抗炎症/免疫
  • 抗感染
  • その他

第7章 エンドユーザー別

  • 病院・診療所
  • 研究機関・研究所
  • 製薬会社・バイオテクノロジー企業
  • その他

第8章 地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
  • 南米
    • ブラジル
    • アルゼンチン
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

第10章 企業プロファイル

  • Merck &Co., Inc
  • Pfizer Inc.
  • Novartis AG
  • Sanofi SA
  • Gilead Sciences, Inc.
  • GSK

第11章 仮定と調査手法

第12章 付録

目次
Product Code: MD9330

The global nanotechnology-enabled drug delivery devices market reached US$ 54.22 billion in 2024 and is expected to reach US$ 179.12 billion by 2033, growing at a CAGR of 12.6% during the forecast period 2025-2033.

Nanotechnology-enabled drug delivery devices are advanced systems that use nanotechnology to improve the efficacy, precision, and safety of therapeutic agents. These devices use nanoscale materials like nanoparticles, liposomes, dendrimers, and polymeric micelles to enhance drug solubility, bioavailability, and targeted delivery to specific tissues or cells. These systems minimize side effects, enhance therapeutic outcomes, and enable personalized treatment approaches, particularly in oncology, neurology, and infectious disease treatments.

Market Dynamics: Drivers & Restraints

Enhanced Drug Bioavailability and Targeted Delivery

The global market for nanotechnology-enabled drug delivery devices is expanding due to its ability to improve drug bioavailability and targeted delivery. These systems enhance therapeutic effectiveness by delivering drugs to specific tissues or diseased cells, minimizing side effects. They are particularly useful in oncology, neurology, and cardiovascular diseases, as they improve solubility, prolong circulation time, and allow controlled drug release. These innovations also facilitate drug transport across biological barriers, making them crucial for treating complex conditions.

Limited Scalability and Manufacturing Complexities

The global nanotechnology-enabled drug delivery devices market faces significant challenges due to the complexities of large-scale manufacturing, including precise engineering, specialized facilities, and strict quality control measures. Variability in nanoparticle size, stability, and drug-loading efficiency can impact product consistency, leading to regulatory setbacks. High costs associated with maintaining advanced manufacturing infrastructure and ensuring batch-to-batch uniformity further restrict market expansion, limiting the widespread adoption of nanotechnology in drug delivery.

Segment Analysis

The global nanotechnology-enabled drug delivery devices market is segmented based on product type, application, end-user and region.

Product Type:

The nanocrystals from product type segment is expected to dominate the nanotechnology-enabled drug delivery devices market with the highest market share

Nanocrystals are a key component in the global drug delivery device market, enhancing the solubility and bioavailability of water-soluble drugs. These ultra-small particles improve drug dissolution rates, leading to faster absorption and increased therapeutic efficacy. They enable controlled, targeted drug release, reducing dosage frequency and side effects. Their applications are particularly significant in oncology, neurology, and cardiovascular treatments. Nanocrystals can be administered via oral, injectable, and topical formulations, expanding their potential across multiple therapeutic areas.

Geographical Analysis

North America is expected to hold a significant position in the Nanotechnology-Enabled Drug Delivery Devices market with the highest market share

North America dominates the global nanotechnology-enabled drug delivery devices market due to strong research, a well-established pharmaceutical industry, and advanced healthcare infrastructure. Major pharmaceutical and biotechnology companies invest in nanotechnology-based solutions. The rising prevalence of chronic diseases like cancer, neurological disorders, and cardiovascular conditions drives demand for innovative drug delivery systems. Collaborations between research institutions and pharmaceutical companies drive innovation, positioning North America as a dominant player.

For instance, according to the Centers for Disease Control and Prevention 6 in 10 Americans have at least one chronic disease, with 4 in 10 having two or more. Preventable chronic diseases are often caused by risky behaviors like smoking, poor nutrition, physical inactivity, and excessive alcohol use.

Hence, North America's increasing chronic disease prevalence drives demand for advanced drug delivery solutions, promoting nanotechnology-enabled devices for treatment efficiency, side effects reduction, and improved patient compliance, boosting market growth.

Competitive Landscape

The major global players in the nanotechnology-enabled drug delivery devices market include Merck & Co., Inc, Pfizer Inc, Novartis AG, Sanofi S.A., Gilead Sciences, Inc, and GSK among others.

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nanotechnology-enabled drug delivery devices market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Enhanced Drug Bioavailability and Targeted Delivery
      • 3.1.1.2. Advancements in Nanotechnology
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Scalability and Manufacturing Complexities
      • 3.1.2.2. High Development and Manufacturing Costs
    • 3.1.3. Opportunity
      • 3.1.3.1. Integration with AI and Smart Drug Delivery Systems
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Force Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Nanocrystals*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Nanoparticles
  • 5.4. Liposomes
  • 5.5. Micelles
  • 5.6. Nanotubes
  • 5.7. Others

6. By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Neurology*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Oncology
  • 6.4. Cardiovascular/Physiology
  • 6.5. Anti-inflammatory/Immunology
  • 6.6. Anti-infective
  • 6.7. Others

7. By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals and Clinics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Research Institutes and Laboratories
  • 7.4. Pharmaceutical and Biotechnology Companies
  • 7.5. Others

8. By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Merck & Co., Inc*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue's
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Pfizer Inc.
  • 10.3. Novartis AG
  • 10.4. Sanofi S.A.
  • 10.5. Gilead Sciences, Inc.
  • 10.6. GSK

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us